Endogenous glucagon‐like peptide (GLP)‐1 as alternative for GLP‐1 receptor agonists: Could this work and how?

In recent years, we have witnessed the many beneficial effects of glucagon‐like peptide (GLP)‐1 receptor agonists, including the reduction in cardiovascular risk in patients with type 2 diabetes, and the reduction of body weight in those with obesity. Increasing evidence suggests that these agents differ considerably from endogenous GLP‐1 when it comes to their routes of action, although their clinical effects appear to be the same. Given the limitations of the GLP‐1 receptor agonists, could it be useful to develop agents which stimulate GLP‐1 release? Here we will discuss the differences and similarities between GLP‐1 receptor agonists and endogenous GLP‐1, and will detail how endogenous GLP‐1—when stimulated appropriately—could have clinically relevant effects. [ABSTRACT FROM AUTHOR]